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ABSTRACT 
Objective: To assess criteria for gout remission and to use the results to inform criteria 
for a complete response (CR). 
Methods:  Post-hoc analysis of two clinical trials were undertaken to determine the 
frequency with which pegloticase-treated subjects with chronic refractory gout met 
remission criteria. Mixed modelling was then employed to identify the components that 
best correlated with time to maximum benefit. 
Results: Of 56 subjects treated with biweekly pegloticase for whom adequate data 
were collected, 48.2% met the remission criteria. When subjects with persistent urate 
lowering were examined separately, 27 of 32 (84.4%) met the criteria for remission. In 
contrast, even when the requirement for serum urate lowering was waived, only 2 of 24 
(8.3%) of those without persistent urate lowering and 0 of 43 subjects receiving placebo 
met criteria. Mixed modelling indicated that in addition to urate levels, assessment of 
tophi, swollen joints, tender joints, and patient global assessment best correlated with 
time to maximum benefit. Using these criteria of CR, 23 of the responders (71.9%) met 
the criteria. All patients who achieved a CR maintained it for a mean duration of 507.4 
days. Finally, 64% of persistent responders to monthly pegloticase also met criteria for 
CR.
Conclusion: These results have validated the proposed remission criteria for gout and 
helped define criteria for CR in individuals with chronic gout treated with pegloticase. 
This composite CR Index can serve as an evidence-based target to inform the design 
and endpoints of future clinical trials.
Significance and Innovations A post-hoc analysis of data from published RCTs of pegloticase in chronic refractory 
gout clearly documented the ability of the proposed remission criteria in gout to 
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distinguish subjects who had persistent urate lowering from those who had only 
transient lowering or received placebo. Using these results and mixed modeling, novel evidence-based criteria for a complete 
response were generated and tested using the data from the pegloticase trials.  71.9% of persistent responders to pegloticase met the criteria of a complete response 
in a mean time of 346 days These composite outcome measures should be useful as endpoints in clinical trials 
and treat to target strategies.
Key Words:  gout, serum urate, remission, outcome
Treating to target is an approach to disease management that considers well-defined 
physiologic targets for controlling disease activity and the means to achieve them.1 This 
approach has become the standard of care in many chronic diseases, including 
hypertension, coronary artery disease, diabetes, and rheumatoid arthritis2,3, and a treat-
to-target approach has been suggested for gout.1,4-6 However, the treatment goals for 
patients with this disease have not been fully defined.7-9  
Treatment goals for gout have typically focused on the biochemical response to 
treatment (i.e., lowering serum urate to <6 mg/dL) and to even lower levels in selected 
patients, such as those with extensive monosodium urate (MSU) crystal deposition.7-9 
However, reaching these levels does not guarantee achievement of clinical goals.  Gout 
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flares may still occur despite urate levels <6.8 mg/dL, the saturation level for urate, 
possibly because of persistent tophi and an increased body urate pool.10
It is likely that in subjects with chronic or advanced gout, the focus on serum urate to 
define success of gout treatment is too narrow and that clinical goals may vary based 
on factors including the burden of MSU crystal deposition, the nature of the clinical 
manifestation, and expectations of patients.11,12 In subjects with advanced gout, 
resolution of tophi is a major goal of treatment, but it is difficult to achieve with current 
oral urate lowering therapy. Even though the development of tophi in subjects with gout 
is related to the serum urate level and the duration of hyperuricemia,13 the relationship 
between urate and tophus development is not precise as only 50% of subjects develop 
obvious tophi within 10 years of an initial gout flare, whereas 28% remain free of tophi 
even 20 years after an initial gout flare.14 Moreover, even though the velocity of 
reduction of tophus burden is correlated with serum urate levels, the correlations 
reported are modest  (r= 0.4 and 0.6)15,16 indicating that other variables influence this 
process. 
Composite indices have been developed to assess the activity of gout and one of these, 
the Gout Activity Score (GAS) has recently been demonstrated to be sensitive to 
change.17-19 However, the GAS measures the level of disease activity in a number of 
domains and does not provide a target for remission of gout activity. A recent Delphi 
exercise focused on defining criteria for remission in gout and reached consensus on a 
multidimensional definition that included serum urate <6 mg/dL, no flares, resolution of 
all tophi, limited pain, and low patient global assessment of disease activity, each with a 
score <2 on a 10 cm visual analog scale.20 Although these proposed remission domains 
have some overlap with those of GAS, they are not identical, including pain as an 
outcome. Moreover, the remission criteria encompass specific goals to be achieved to 
consider a subject to have achieved remission. Although the criteria for remission were 
proposed, they have not been tested in longitudinal clinical trials.  Moreover, their utility 
in chronic or advanced gout have not been examined. 
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This study therefore, evaluated the utility of these proposed criteria using clinical results 
from patients with chronic refractory gout who received pegloticase (8 mg every 2 
weeks), a mammalian recombinant uricase conjugated to polyethylene glycol that is 
approved for treatment of adult patients with chronic gout refractory to oral urate 
lowering therapy. Specifically, all clinical data from subjects collected at each clinical 
visit were evaluated by an independent investigator to determine whether the subject 
met remission criteria at that visit.20
PATIENTS AND METHODS
Design of Pegloticase Clinical Trials
Results from two identical randomized controlled trials (RCTs) of pegloticase and their 
open-label extension (OLE) (NCT00325195, NCT01356498) were analyzed. The 
methods for these studies have been described in detail, and they will be summarized 
only briefly here.21,22 
Patients were 18 years of age with chronic refractory gout, defined as baseline sUA 8.0 mg/dL, and 1 of the following: 1) 3 self-reported gout flares during the previous 
18 months; 2) 1 tophi; and 3) gouty arthropathy, defined clinically or radiographically 
as joint damage caused by gout; and contraindication to treatment with allopurinol or 
history of failure to normalize sUA despite 3 months of treatment with the maximum 
medically appropriate allopurinol dose as determined by the treating physician. Patients 
were randomized to 6 months of treatment with intravenous infusions of either 
pegloticase 8 mg at each infusion, pegloticase 8 mg alternating with placebo, or 
placebo.21 Flare prevention medication (hydrocortisone and anti-histamines) was given 
to all subjects. After the RCT, subjects were given the option of entering an OLE to 
assess the persistence of the response.
A responder to treatment (primary endpoint for the RCTs) was defined as a patient with 
serum urate <6.0 mg/dL for 80% of the time during months 3 and 6. Nonresponders 
were all other subjects, including those who left the study early. Secondary endpoints
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included tophus resolution; reductions in the proportion of patients with gout flares and 
in the number of flares per patient during months 1-3 and 4-6 of the trial; reductions in 
tender and swollen joint counts; and, patient-reported changes in pain, physical 
function, and quality of life, measured respectively, by the Health Assessment 
Questionnaire (HAQ) pain scale, HAQ–Disability Index (HAQ-DI), and 36-Item Short 
Form Health Survey (SF-36).21 This study was completed before the remission criteria 
were proposed, and remission was not an outcome measure.
Tophus assessment was carried out using Computer Assisted Photographic Evaluation 
in Rheumatology (CAPER) methodology.23 Photographs of the hands and feet were 
taken for each patient at baseline. Photographs of up to two additional regions were 
taken at the discretion of the investigator based on other tophi identified at baseline. 
Digital media cards containing the photographs were sent to RadPharm (Princeton, NJ, 
USA) where central readers, who were blinded to treatment assignment, evaluated the 
photographs prospectively and identified sites of tophi present at the start of treatment 
as well as response to therapy. Patients completing either of two replicate RCTs were 
eligible to enter an open-label extension (OLE) for up to 3 years in which they received 
pegloticase 8 mg every 2 weeks.  Safety was evaluated as the primary outcome, but the 
above described efficacy variables were also assessed.22
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Relating Clinical Responses to Published Criteria for Gout Remission
Of the 85 subjects who entered the RCTs and received pegloticase 8 mg biweekly, a 
total of 56 proceeded into the OLE and sufficient data were collected to assess whether 
they met criteria of remission. Of these subjects, 36 were responders to treatment in the 
RCTs (persistent serum urate <6mg/dL), 34 of these subjects entered the OLE20, and 
32 had adequate data collected to assess. Of those without persistent urate lowering in 
the RCT (nonresponders), 24 proceeded into the OLE and had sufficient data collected 
to be analyzed. Initially, individual patient data from each clinic visit was reviewed by an 
independent evaluator to establish the frequency with which subjects met the proposed 
remission criteria. To be classified as meeting remission criteria, a subject was required 
to have a serum urate <6mg/dL, no flares during the time since the last visit, no 
detectable tophi, and pain and patient global assessment <2 on a 10 cm visual analog 
scale. Only subjects who met all 5 criteria were considered to meet criteria of remission. 
Subsequently, this group of subjects was employed to determine new criteria for a 
“complete response” (CR) by using mixed modelling. A repeated measures, mixed 
effects model controlling for repeated observations was used to relate the time when a 
response was noted in patient global assessment (PGA) scores, SF-36 bodily pain 
scores, VAS pain levels, number of tender joints (TJC), number of swollen joints (SJC), 
the number of flare episodes, and the degree of tophus resolution. Variables were then 
excluded by using backward elimination of the least statistically significant term. The 
final model included all terms that were statistically significant. The results from the 
analysis of patients who responded to administration of pegloticase every 2 weeks was 
validated with a second analysis of results for patients who responded to administration 
of pegloticase every 4-weeks in the RCTs. 
Additional analyses carried out using results from this patient cohort included: 1) time to 
achieve remission according to the criteria set forth in the Delphi exercise20; 2) 
correlations among components of remission and CR for patients meeting the criteria 
for remission; 3) the relationship between flares, serum urate levels, and clinical 
characteristics for patients meeting the criteria for remission; 4) time to CR for all 
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responders in the RCTs for pegloticase; and, 5) the relationship between time to 
achieve CR and duration of that response.
The relationships between flares and other clinical variables, tender and swollen joint 
counts, VAS pain, SF-36 pain, PGA, percent reduction from baseline in tophus area, 
and sUA, were also evaluated for all 56 patients (responders and non-responders) who 
were treated with pegloticase every 2 weeks in the RCTs and who continued into the 
OLE. Each subject was evaluated every 2 weeks and if a flare was reported the values 
for all measures were evaluated at the subsequent visit to determine the association 
with the flare.  If no flare was reported for the 2 weeks before the evaluation, all 
measures were considered to be unrelated to flares. Values for each measure that were 
associated or not associated with flares were compared with Wilcoxon signed-ranks 
tests.
RESULTS
Achievement of Remission
Of 56 evaluable subjects treated with biweekly pegloticase, 27 (48.2%) met criteria for 
remission (Figure 1A). Since this group of subjects included both those who had 
persistent urate lowering in response to pegloticase (n=32) and those with only transient 
urate lowering (n= 24), it was of interest to determine whether the attainment of 
remission was associated with persistent urate lowering. Of the 32 pegloticase 
responders in the RCTs who entered the OLE, 27 (84.4%) met the criteria for remission 
(Figure 1B). When the requirement of serum urate <6 mg/dL was waived, only 2 of 24 
(8.3%) of nonresponders and 0 of 43 (0.0%) of subjects receiving placebo met clinical 
criteria for remission. The times to achieve remission for all pegloticase responders in 
the RCTs and for those who met the criteria for remission are shown in Figure 1B. The 
length of time required for 50% of patients to achieve remission was 252 days (8.4 
months) for all responders and 181 days (6.0 months) for responders who achieved 
remission. 
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Relationships between Flares, Serum Urate Levels and Patient Clinical 
Characteristics 
In order to determine whether the various domains of the “remission” model contributed 
information, we attempted to develop correlations between the various components. 
First, we assessed relationships between gout flares and other variables. As can be 
seen in Figure 2, all clinical variables were significantly worse at the time of a flare 
compared to assessments when there was no flare.  However, the variance was great 
and the differences, albeit statistically significant, were small.  Notably, there was no 
significant difference between the serum urate at the time of a flare or at other times. To 
examine this in greater detail, we assessed each clinical variable at the time of flares in 
the 26 subjects who met criteria of remission and experienced flares.  As can be seen in 
Figure 3, PGA for example, varied widely at the times of flares in these subjects. Table 
1 shows correlations between all components of remission and other clinical features in 
the 29 responders meeting criteria of “remission”. Results of this analysis indicated 
weak or absent correlations among many of these variables. The highest correlation 
noted was between the two pain assessments (r=0.79), whereas the association 
between pain and TJC was lower (r=0.32-0.34); and, the association between pain and 
SJC was even less (r=0.16-0.23). Even the association between pain and PGA was 
modest (r=0.45-0.49). These results indicate that the components of the “remission” 
criteria may not all be improving contemporaneously in subjects with chronic or 
advanced gout and that other sets of characteristics may be more effective at defining a 
state of disease quiescence.
Results of Mixed Modelling
To develop new composite criteria for a CR from this data set, repeated measures, 
mixed effects modelling with backward elimination of components with the least 
statistical significance was carried out. Since gout is a chronic disease with a genetic 
predisposition and a biochemical underpinning, the new composite outcome measure 
determined from mixed modelling was considered to be a CR rather than “remission.” 
Final criteria for CR were: serum urate <6 mg/dL, resolution of all measured tophi, PGA 
≤1, SJC ≤1, and TJC ≤1. 
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Achievement and Maintenance of CR
The time to achieve a CR for all 34 responders is shown in Figure 4A. Of the 32 
responders, 23 (71.9%) met the criteria of a CR. The time for 50% of patients to achieve 
a CR was 346 days. All patients who achieved a CR maintained it until the end of 
follow-up. The mean duration of CR was 507.4 days. There was a significant inverse 
relationship between the time to CR and the duration of the response (P=0.0008), 
Figure 4B. 
Analysis of Results for Patients Who Responded to Administration of Monthly 
Pegloticase 
The additional analysis of 25 patients who responded to administration of pegloticase 
every 4 weeks and completed the RCTs indicated that 16 (64%) met the criteria for a 
CR and that 50% of this subgroup achieved this response in 424 days (Figure 5).
DISCUSSION
We report herein, the first effort to validate the proposed remission criteria in gout, using 
a dataset from a therapeutic intervention. The proposed criteria for remission had been 
developed by Delphi consensus exercises, but had not been tested using a dataset 
from a randomized clinical trial.20 This post-hoc evaluation indicated that 85.3% of 
responders to biweekly pegloticase met the criteria for remission, which included       
serum urate <6 mg/dL, no tophi, no flares, pain <2 on a 10 cm visual analog scale, and 
PGA <2 on a 10 cm visual analog scale. These criteria were assessed at each clinic 
visit by an independent evaluator who reviewed the individual patient records and all 5 
criteria were required to be present contemporaneously for the subject to be considered 
as meeting the criteria of remission. Importantly, the clinical components of the criteria 
(omitting serum urate) could also distinguish between those with persistent lowering of 
serum urate (responders) and those without persistent urate lowering (non-responders) 
to the study medication and also between treated subjects and those receiving placebo. 
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Therefore, the proposed remission criteria clearly appeared to be effective in 
distinguishing the quality of the response in subjects with chronic refractory gout treated 
with pegloticase.  Notably however, there was modest or no correlation between many 
components of the remission criteria. This suggested that the remission criteria were not 
ideal in assessing the quality of responses in chronic or advanced gout and that an 
alternative model might be more effective. Using a repeated effects mixed model with 
backward elimination, criteria for a CR in chronic or advanced gout were developed. 
Using these criteria, the vast majority of individuals (71.9%) with chronic or advanced 
gout treated with pegloticase who achieved persistently lower serum urate levels, 
reached criteria for CR; 50% of pegloticase-treated patients achieved CR in 11.5 
months. The results from the subjects in the RCTs who responded to treatment with 
intravenous pegloticase administered every 2 weeks were validated with a second 
independent analysis of clinical results of patients treated with monthly intravenous 
pegloticase who met the response criteria in the RCT; 64% of these patients met the 
criteria for a CR with 50% achieving this response in 424 days. Although this validation 
exercise is not ideal because these subjects were part of the same RCTs that were 
used to generate the CR criteria, few other clinical trial data sets are available with 
sufficient clinical impact to assess the induction of a CR.
Although optimistically biased, the results from the monthly pegloticase cohort are 
intriguing because they suggest that fewer subjects in the monthly pegloticase 
treatment group achieve a CR and that it takes a longer period of treatment than was 
determined in the group receiving biweekly pegloticase, a result suggested in the RCTs, 
in which monthly pegloticase was less effective.21 All of these results support the view 
that a composite index to determine a CR could be useful in a treat to target strategy.
It should be noted that the Delphi exercise20 and the present study are not the only 
efforts to develop a composite measure of disease control in patients with gout. In one 
retrospective chart review, disease control for patients with gout was defined as a 12-
month average serum urate ≤6 mg/dL, no flares, and no tophi, three of the five criteria in 
the proposed remission criteria; and it was noted that only 11% of 858 patients whose 
records were evaluated achieved this goal.24 The Outcomes in Rheumatology Clinical 
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Trials (OMERACT) also endorsed specific domains that should be assessed in clinical 
trials of therapies for chronic gout and corresponding instruments for their 
measurement.25  Based on OMERACT core domains and Delphi exercises, the GAS 
was developed. The first candidate GAS included seven indicators: 1) 12-month flare 
count; 2) serum urate; 3) pain (VAS); 4) VAS global activity assessment; 5) SJC; 6) 
TJC; and 7) cumulative measure of tophi.  A second iteration included flares, serum 
urate, patient global assessment and the number of tophi. This final GAS demonstrated 
a good correlation with functional disability (criterion validity) and discrimination between 
patient- and physician-reported measures of active disease (construct validity).17 In 
comparing different response criteria, it should be noted that those selected on the 
basis of the analysis carried out in the present study were the first set to be derived from 
data in a clinical trial, to clearly show responsiveness to change and to focus on chronic 
or advanced gout. 
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The present results, particularly the weak relationship between the occurrence of flares 
and other response measures in the patients who achieved remission, challenge the 
utility of this outcome. The findings that there were modest or absent correlations 
between many of the clinical characteristics and that there was wide variation in clinical 
features at the time of a flare support the results of the repeated measures, mixed 
effects modelling that did not include absence of flares in the criteria for a CR. The lack 
of a strong relationship between flares and other clinical characteristics should not be 
taken as evidence that flares are unimportant in patients with gout. This view is 
supported by results for all patients who received pegloticase every 2 weeks which 
showed that tender and swollen joint counts, pain, and PGA were all significantly worse 
near the times of flares vs times when flares had not occurred. The absence of a 
relationship between flares and other variables and the high variability in PGA scores at 
the time of flares in patients who met the criteria for remission may be related to the 
very broad definition of flares in these studies, which was "self-reported acute joint pain 
and swelling requiring treatment".21 A more rigorous flare definition, such as the one 
recently proposed by Gaffo et al. (i.e., presence of ≥ 3 out of 4 criteria: 1) patient-
defined gout flare, 2) pain at rest >3 on a 0-10 numeric rating scale, 3) presence of at 
least one swollen joint, and 4) presence of at least one warm joint ) may be more 
suitable for use in future studies of gout treatment and could result in flares being 
included in CR criteria.26
It has been noted that when establishing treatment targets, clinicians should consider 
outcomes most important to patients27, and results from one analysis have suggested 
that development of a composite outcome may be difficult from this perspective. Results 
from a study in which three patient groups rated the importance of different outcomes, 
indicated that the relative importance accorded to each outcome domain was different 
across the groups. Both the presence of tophi and pain between flares were ranked as 
less important, whereas gout flares were ranked as more important and the relative 
importance of serum urate and activity limitations was variable.27 The relatively low 
importance of tophi to patients in this study is surprising since an assessment of 110 
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patients with severe “treatment failure” gout showed that the presence of tophi was 
associated with significantly worse bodily pain, general health, role-physical, social 
functioning, vitality, and Physical Component Score as measured by the SF-36.28  
However, another analysis indicated that frequency of flares and severity and duration 
of pain, but not serum urate or the presence of tophi and the number of joints involved 
in a typical flare, significantly impacted the patient's quality of life.29 The development of 
evidence-based criteria for CR may provide the basis for future examination of the 
relationship between patient expectations and results of clinical trials and provide more 
effective goals for a treat- to-target strategy.
There are limitations to this study. First, the data were derived from two identical RCTs 
with an OLE and will require confirmation with other data sets. Secondly, as mentioned 
above, the results of the validation exercise for the CR criteria were likely to be 
optimistically biased as they were obtained from a cohort of the same RCTs used to 
generate the composite measure. Finally, this analysis was carried out in a group of 
subjects with advanced gout who met entry criteria for a clinical trial of subjects with 
chronic refractory gout. Whether the proposed criteria will be useful in subjects with less 
advanced gout remains to be determined. Regardless, the data provide a first step in 
validating the proposed criteria for remission in gout and suggest an additional 
evidenced-based set of criteria to identify subjects with a CR.
In conclusion, the present study employed clinical trial data to validate the proposed 
gout remission criteria and also to define criteria that tended to track together more than 
the components of the remission criteria.  This composite complete responder measure 
can serve as an evidence-based target to inform the design and endpoints of future 
urate lowering therapy trials in chronic gout.
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Tables 
Table 1. Correlations between all components of remission and other clinical
features in the 29 serum urate responders meeting criteria of “remission”.
SF-36 
pain VAS pain SJC TJC PGA
Tophus 
Category Variable
-0.34787 0.22553 -0.09753 0.00727 0.13198 0.00523
Serum 
urate
<.0001 0.0004 0.0854 0.8982 0.0201 0.9493 P-value
 -0.79152 -0.23102 -0.34343 -0.49247 -0.13874 SF-36 pain
 <0.0001 0.0006 <0.0001 <0.0001 0.0915 P-value
  0.15509 0.32799 0.45337 0.20606 VAS pain
  0.0226 <0.0001 <0.0001 0.0123 P-value
   0.55837 0.57825 -0.04911 SJC
Tophus Category <0.0001 <0.0001 0.5506 P-value
 Progressive disease = 2 0.63261 0.0923 TJC
 Stable disease = 3 <0.0001 0.2613 P-value
 Partial response = 4  0.0688 PGA
 Complete response = 5 0.4028 P-valueAu
th
or
 M
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us
cr
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t
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Figure Legends 
Figure 1A-B. Time to achieve criteria of “remission” in A. Entire group of subjects 
treated with biweekly pegloticase B. Subjects meeting the criteria of 
responder and having persistent urate lowering. The two lines in B 
represent data from the entire responder cohort (n=32) and those who met 
criteria for remission (n=27)
Figure 2. Mean values (+ standard deviations [SD]) for clinical measures taken at 
clinical visits that were or were not associated with flares. Results are for 
all patients (n=56) treated with pegloticase every 2 weeks in the RCTs and 
OLE. There were 147 observations associated with flares and 201 
observations not associated with flares
Figure 3. Values for PGA at the time of flares for q2w responders who met the 
criteria for remission
Figure 4.  A. Time to CR (sUA responders in RCTs)
 B. Relationship between time to achieve CR and duration of response
           
Figure 5. Time to CR for patients who responded to administration of pegloticase 
every 4 weeks; CR was achieved by 16 (64%) of 24 patients with 50% 
achieving this response in 424 days
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